Suman Reddy, MD
Nephrology · Bronx, NYNPI 1447363247
Payments from drug & device makers
Across 241 payments — averaging $31.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Amgen$966
- Johnson & Johnson$866
- Vifor Pharma, Inc.$749
- Boehringer Ingelheim$654
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$2003%
- Food & beverage$7,40497%
- Education$411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 62 | $1,383 |
| Novo Nordisk | 16 | $1,052 |
| Amgen(2 entities) | 35 | $966 |
| Johnson & Johnson | 9 | $866 |
| Vifor Pharma, Inc. | 30 | $749 |
| Boehringer Ingelheim | 7 | $654 |
| Akebia Therapeutics Inc | 15 | $359 |
| Aurinia Pharma U.S., Inc. | 8 | $193 |
| Bayer | 8 | $188 |
| Travere Therapeutics, Inc. | 7 | $160 |
| Lilly USA, LLC | 6 | $158 |
| E.r. Squibb & Sons, L.L.C. | 1 | $131 |
| Otsuka America Pharmaceutical, Inc. | 4 | $86 |
| Exact Sciences | 3 | $83 |
| Calliditas Therapeutics US Inc. | 2 | $60 |
| Pfizer | 4 | $59 |
| Ardelyx, Inc. | 3 | $55 |
| Merck | 3 | $51 |
| Medtronic | 2 | $48 |
| GSK | 2 | $46 |
| Shield Therapeutics Inc | 2 | $46 |
| Fresenius USA Marketing, Inc. | 2 | $42 |
| Alnylam Pharmaceuticals Inc. | 2 | $39 |
| Scpharmaceuticals Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $27 |
| Novartis | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $24 |
| OPKO Pharmaceuticals, LLC | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $16 |
| Renalytix AI, Inc. | 1 | $16 |
| Dexcom, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,645 in reported general payments places this provider in the 80th percentile of 935 nephrology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 231 | $196,680 |
| JardianceEmpagliflozin | 86 | $104,598 |
| TrulicityDulaglutide | 68 | $77,284 |
| VeltassaPatiromer Calcium Sorbitex | 49 | $51,156 |
| AranespDarbepoetin Alfa In Polysorbat | 53 | $42,080 |
| OzempicSemaglutide | 29 | $32,703 |
| EliquisApixaban | 32 | $25,457 |
| LokelmaSodium Zirconium Cyclosilicate | 28 | $21,046 |
| ProcritEpoetin Alfa | 20 | $19,010 |
| Sevelamer Carbonate | 117 | $18,607 |
| AuryxiaFerric Citrate | 14 | $14,675 |
| KerendiaFinerenone | 12 | $13,032 |
| JanuviaSitagliptin Phosphate | 14 | $8,816 |
| DapagliflozinDapagliflozin Propanediol | 12 | $6,415 |
| Nifedipine ErNifedipine | 185 | $4,570 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $1,383 | $217,725259 claims |
| Boehringer IngelheimJardiance | $654 | $104,59886 claims |
| Lilly USA, LLCTrulicity | $158 | $77,28468 claims |
| AmgenAranesp | $966 | $42,08053 claims |
| Novo NordiskOzempic | $1,052 | $32,70329 claims |
| PfizerEliquis | $59 | $25,45732 claims |
| Johnson & JohnsonProcrit | $866 | $19,01020 claims |
| Akebia Therapeutics IncAuryxia | $359 | $14,67514 claims |
| BayerKerendia | $188 | $13,03212 claims |
| MerckJanuvia | $51 | $8,81614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 935 nephrology providers in New York.
Other nephrology in Bronx
- Robert LynnBronx$2M
- Bruce SpinowitzBronx$837K
- Matthew AbramowitzBronx$749K
- Enver AkalinBronx$312K
- Chang XuBronx$257K
- Joel NeugartenBronx$256K
- Chaim CharytanBronx$204K
- Gill FreiBronx$188K
- Joji TokitaNew York$8.4M
- Krzysztof KirylukNew York$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.